Aurinia Pharmaceuticals Inc. (AUPH)

5.03 -0.06 (-1.18%) 收市：04:00PM EDT

Aurinia Pharmaceuticals Inc.

118 Avenue , 14315
Suite 140
Edmonton, AB T5L 4S6
Canada
250 744 2487
https://www.auriniapharma.com

版塊: Healthcare
行業: Biotechnology
全職員工: 300

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Peter S. Greenleaf M.B.A.	President, CEO & Director	1.34M	無	1970
Mr. Joseph M. Miller CPA	Chief Financial Officer	791.92k	無	1974
Mr. Matthew Maxwell Donley M.B.A.	Executive Vice President of Operations & Strategy	811.82k	無	1969
Mr. Stephen P. Robertson	Executive VP, General Counsel, Corporate Secretary & Chief Compliance Officer	739.68k	無	1982
Dr. Volker Knappertz D.Sc., M.D.	Executive Vice President of Research & Development	742.85k	無	1965
Andrea Levin Christopher	Head of the Corporate Communications & Investor Relations	無	無	無
Mr. Fran Lynch	Vice President of Sales	無	無	無
Mr. Michael R. Martin	Chief Business Officer	350.57k	無	1972
Ms. Sue Evans	Senior Vice President of Global Regulatory Affairs	無	無	無
Mr. Scott Habig	Chief Commercial Officer	無	無	1960

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

公司管治

截至 2024年4月1日 止，Aurinia Pharmaceuticals Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：8；董事會：5；股東權利：2；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。